Differential diagnosis
Intussusception should be considered, even if the typical purpuric rash has evolved (intussusception occurs in 2-3% of HSP patients). Connective tissue diseases -eg, systemic lupus erythematosus (SLE). Other causes of purpuric rash -eg, thrombocytopenia. Other causes of glomerulonephritis. Acute haemorrhagic oedema of infancy: self-limiting condition presenting with fever, oedema and rosette-shaped, annularshaped or targetoid-shaped purpura affecting the face, ears and extremities. [6] Investigations Diagnosis of HSP is clinical and not based on laboratory investigations. [4] The following abnormalities may be present:
Urinalysis: haematuria and/or proteinuria are present in 20-40% of patients. [1, 4] FBC: there may be raised white cell count with eosinophilia; normal or increased platelets. 
Management
HSP is usually self-limiting and no form of therapy has been shown appreciably to shorten the duration of disease or prevent complications. Therefore, treatment for most patients remains primarily supportive. Non-steroidal anti-inflammatory drugs (NSAIDs) may help joint pain but should be used with caution in patients with renal insufficiency. May require admission to hospital for monitoring of abdominal and renal complications. Nephropathy: treated supportively. A variety of drugs (steroids, azathioprine, cyclophosphamide) and plasmapheresis have been used to prevent the progression of the renal disease but the results of trials have been inconsistent. Corticosteroids can ameliorate associated arthralgia and the symptoms associated with gastrointestinal dysfunction. There was no evidence of benefit of prednisone in preventing serious long-term kidney disease in HSP. [7, 8] No controlled clinical trials have been performed with immunosuppressive drugs, although azathioprine or cyclophosphamide may be beneficial. Plasma exchange is used in the management of some adults with vasculitis and idiopathic rapidly progressive nephritis. [9] Complications Renal involvement occurs in 50% of older children but is only serious in approximately 10% of patients. Less than 1% of patients with HSP progress to end-stage kidney disease. The renal prognosis is worse in older children and adults. [4] Monitoring for renal involvement: [1] For those with no proteinuria, recommendations are for blood pressure checking and urinalysis at days 7 and 14 and at 1, 3, 6 and 12 months. For those with proteinuria, follow-up is recommended at days 7 and 14, monthly from 1-6 months and then at 12 months.
Other rare complications include myocardial infarction, pulmonary haemorrhage, pleural effusion, intussusception (in 2-3% of patients), gastrointestinal bleeding, bowel infarction, seizures and mononeuropathies. Recurrence of symptoms may occur. Recurrence of renal impairment may also occur but is rare.
Prognosis
HSP is an acute self-limited illness and usually resolves without treatment, but may rarely lead to complications. Initial attacks of HSP can last for several months. One in every four patients will have one or more recurrences. [10] Children younger than 3 years have a shorter, milder course and fewer recurrences. Chronic kidney disease may progress, sometimes more than ten years after the initial flare. [11] The long-term prognosis of HSP is directly dependent on the severity of renal involvement. [5] One study reported that adults with HSP had a higher frequency of renal insufficiency and worse renal outcomes than children. [12] Further reading & references 
